TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01504334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: Pirfenidone（200mg）tablets will be taken 3 times a day during the whole study process. For the first week, 1 tablet will be taken each time. For the second week, 2 tablets will be taken each time. From the third week to the 48th week, 3 tablets will be taken each time. Base drug Acetyl Cysteine Tablets（600mg）will be taken once a day, 1 tablet each time from the first to the 48th week.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo（without active ingredient） tablets will be taken 3 times a day during the whole study process. For the first week, 1 tablet will be taken each time. For the second week, 2 tablets will be taken each time. From the third week to the 48th week, 3 tablets will be taken each time. Base drug Acetyl Cysteine Tablets（600mg）will be taken once a day, 1 tablet each time from the first to the 48th week for both groups.
Study: NCT03981315

Intervention type: DIAGNOSTIC_TEST
Intervention: Gall stone study
Description: Study of the extracted gall stones, analyzing their composition, type, etc.

Intervention type: DIAGNOSTIC_TEST
Intervention: Gall stone study
Description: Study of the extracted gall stones, analyzing their composition, type, etc.

Intervention type: DIAGNOSTIC_TEST
Intervention: Microbiological bile test
Description: Determination of the microbiological composition of the bile

Intervention type: DIAGNOSTIC_TEST
Intervention: Microbiological bile test
Description: Determination of the microbiological composition of the bile

Intervention type: DIAGNOSTIC_TEST
Intervention: Microbiological bile test
Description: Determination of the microbiological composition of the bile
Study: NCT00684645

Intervention type: DRUG
Intervention: SUTENT
Description: SUTENT® hard gelatin capsules containing 12.5 mg, 25 mg or 50 mg equivalent of sunitinib malate; daily dosage of 50 mg for 4 consecutive weeks followed by a 2-week rest period. Sutent is administered until disease progression or occurrence of unacceptable toxicity.
Study: NCT00740532

Intervention type: GENETIC
Intervention: Gene mutation analyses and FISH
Description: FISH and mutation analyses of multiple genes
Study: NCT01246297

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Rehabilitation
Description: Twice weekly exercise classes with an education component. For 8 weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual post operative care
Description: Usual post operative care for post lung lobectomy patients for 8 weeks post discharge.
Study: NCT00623883

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical removal of ACF
Description: All ACF removed by either cold or hot colonoscopic biopsy forceps

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Colonoscopic evaluation only
Description: Stain-enhanced magnification endoscopy performed, ACF quantified at entry and after one year
Study: NCT03188965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elimusertib (BAY1895344)
Description: Solution or tablet, oral, to be administered until evidence of tumor progression, unacceptable toxicity, consent withdrawal, or withdrawal from the study at the discretion of the investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elimusertib (BAY1895344)
Description: Solution or tablet, oral, to be administered until evidence of tumor progression, unacceptable toxicity, consent withdrawal, or withdrawal from the study at the discretion of the investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elimusertib (BAY1895344)
Description: Solution or tablet, oral, to be administered until evidence of tumor progression, unacceptable toxicity, consent withdrawal, or withdrawal from the study at the discretion of the investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elimusertib (BAY1895344)
Description: Solution or tablet, oral, to be administered until evidence of tumor progression, unacceptable toxicity, consent withdrawal, or withdrawal from the study at the discretion of the investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elimusertib (BAY1895344)
Description: Solution or tablet, oral, to be administered until evidence of tumor progression, unacceptable toxicity, consent withdrawal, or withdrawal from the study at the discretion of the investigator.
Study: NCT02976389

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Financial Incentive: High
Description: dlParticipants in this group will receive an additional $40/month to use towards the purchase of SNAP eligible fruits and vegetables. They will be able to access these dollars through an electronic wallet (e-wallet) that is tied to their customer loyalty card. They will also have access to the fruit and vegetable promotions that include discount pricing and SNAP-Ed programming (e.g., in-store cooking classes, tours, and healthy food self-labeling system) to educate and support the purchasing behaviors of SNAP-eligible families.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Financial Incentive: Middle
Description: Participants in this group will receive an additional $20/month to use towards the purchase of SNAP eligible fruits and vegetables. They will be able to access these dollars through an electronic wallet (e-wallet) that is tied to their customer loyalty card. They will also have access to the fruit and vegetable promotions that include discount pricing and SNAP-Ed programming (e.g., in-store cooking classes, tours, and healthy food self-labeling system) to educate and support the purchasing behaviors of SNAP-eligible families.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Financial Incentive: Low
Description: Participants in this group will receive an additional $10/month to use towards the purchase of SNAP eligible fruits and vegetables. They will be able to access these dollars through an electronic wallet (e-wallet) that is tied to their customer loyalty card. They will also have access to the fruit and vegetable promotions that include discount pricing and SNAP-Ed programming (e.g., in-store cooking classes, tours, and healthy food self-labeling system) to educate and support the purchasing behaviors of SNAP-eligible families.
Study: NCT03707145

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Consultation
Description: The consultation will provide advice (including a short written report) about promoting healthy lifestyles, tailored to the individual

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Consultation
Description: The consultation will provide advice (including a short written report) about promoting healthy lifestyles, tailored to the individual

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Consultation
Description: The consultation will provide advice (including a short written report) about promoting healthy lifestyles, tailored to the individual
Study: NCT02906670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym013
Description: Sym013 is a recombinant antibody mixture containing 6 humanized immunoglobulin G1 (IgG1) monoclonal antibodies (mAbs), which bind specifically to non-overlapping epitopes or domains on the epidermal growth factor receptor (EGFR), and the human epidermal growth factor receptors (HER) HER2 and HER3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym013
Description: Sym013 is a recombinant antibody mixture containing 6 humanized immunoglobulin G1 (IgG1) monoclonal antibodies (mAbs), which bind specifically to non-overlapping epitopes or domains on the epidermal growth factor receptor (EGFR), and the human epidermal growth factor receptors (HER) HER2 and HER3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym013
Description: Sym013 is a recombinant antibody mixture containing 6 humanized immunoglobulin G1 (IgG1) monoclonal antibodies (mAbs), which bind specifically to non-overlapping epitopes or domains on the epidermal growth factor receptor (EGFR), and the human epidermal growth factor receptors (HER) HER2 and HER3.
Study: NCT03707145

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Consultation
Description: The consultation will provide advice (including a short written report) about promoting healthy lifestyles, tailored to the individual
Study: NCT02906670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym013
Description: Sym013 is a recombinant antibody mixture containing 6 humanized immunoglobulin G1 (IgG1) monoclonal antibodies (mAbs), which bind specifically to non-overlapping epitopes or domains on the epidermal growth factor receptor (EGFR), and the human epidermal growth factor receptors (HER) HER2 and HER3.
Study: NCT03707145

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Support
Description: The participant will have access to an online platform 'FACET', to monitor themselves periodically, obtain feedback about their functional ability, receive recommended diet, exercise and physical activity interventions and record the adherence to any intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online Support
Description: The participant will have access to an online platform 'FACET', to monitor themselves periodically, obtain feedback about their functional ability, receive recommended diet, exercise and physical activity interventions and record the adherence to any intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empowered
Description: The participant will be actively encouraged to contribute to their own consultation and take co-ownership and responsibility for the action plan.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Empowered
Description: The participant will be actively encouraged to contribute to their own consultation and take co-ownership and responsibility for the action plan.
Study: NCT02906670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym013
Description: Sym013 is a recombinant antibody mixture containing 6 humanized immunoglobulin G1 (IgG1) monoclonal antibodies (mAbs), which bind specifically to non-overlapping epitopes or domains on the epidermal growth factor receptor (EGFR), and the human epidermal growth factor receptors (HER) HER2 and HER3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym013
Description: Sym013 is a recombinant antibody mixture containing 6 humanized immunoglobulin G1 (IgG1) monoclonal antibodies (mAbs), which bind specifically to non-overlapping epitopes or domains on the epidermal growth factor receptor (EGFR), and the human epidermal growth factor receptors (HER) HER2 and HER3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym013
Description: Sym013 is a recombinant antibody mixture containing 6 humanized immunoglobulin G1 (IgG1) monoclonal antibodies (mAbs), which bind specifically to non-overlapping epitopes or domains on the epidermal growth factor receptor (EGFR), and the human epidermal growth factor receptors (HER) HER2 and HER3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym013
Description: Sym013 is a recombinant antibody mixture containing 6 humanized immunoglobulin G1 (IgG1) monoclonal antibodies (mAbs), which bind specifically to non-overlapping epitopes or domains on the epidermal growth factor receptor (EGFR), and the human epidermal growth factor receptors (HER) HER2 and HER3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym013
Description: Sym013 is a recombinant antibody mixture containing 6 humanized immunoglobulin G1 (IgG1) monoclonal antibodies (mAbs), which bind specifically to non-overlapping epitopes or domains on the epidermal growth factor receptor (EGFR), and the human epidermal growth factor receptors (HER) HER2 and HER3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym013
Description: Sym013 is a recombinant antibody mixture containing 6 humanized immunoglobulin G1 (IgG1) monoclonal antibodies (mAbs), which bind specifically to non-overlapping epitopes or domains on the epidermal growth factor receptor (EGFR), and the human epidermal growth factor receptors (HER) HER2 and HER3.
Study: NCT04850339

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ANXV
Description: Intravenous infusion

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ANXV
Description: Intravenous infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion
Study: NCT01152073

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each subject will be expected to consume a twice daily drink of approximately 4 ounces per serving taken with the morning and evening meals for a total of 8 weeks. Each bottle will contain two servings.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Second Formulation
Description: Each subject will be expected to consume a twice daily drink of approximately 4 ounces per serving taken with the morning and evening meals for a total of 8 weeks. Each bottle will contain two servings.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Third Formulation
Description: Each subject will be expected to consume a twice daily drink of approximately 4 ounces per serving taken with the morning and evening meals for a total of 8 weeks. Each bottle will contain two servings.
Study: NCT03082859

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: This a randomised cross-over study involving three different modes of exercise which will be compared to a no-exercise control.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: This a randomised cross-over study involving three different modes of exercise which will be compared to a no-exercise control.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: This a randomised cross-over study involving three different modes of exercise which will be compared to a no-exercise control.
Study: NCT01195311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB024360
Description: INCB024360: 25 mg and 100 mg tablets Doses will be escalated in accordance with the dosing schedule.
Study: NCT02976857

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C-CAR-011
Description: lymphocytes will be transduced with lentiviral vector containing CAR-CD19 gene.
Study: NCT02957383

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wavelength
Description: wavelength at two levels: short (SWL)-485 nm (13500k) and long (LWL)-620 nm (4250k)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wavelength
Description: wavelength at two levels: short (SWL)-485 nm (13500k) and long (LWL)-620 nm (4250k)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensity
Description: Luminance at two levels: low - 80 lux (35mw/cm2) and high - 350 lux (160mw/cm2

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensity
Description: Luminance at two levels: low - 80 lux (35mw/cm2) and high - 350 lux (160mw/cm2
Study: NCT02792517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab
Description: A single dose of erenumab administered in the abdomen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethynil Estradiol/Norgestimate Oral Contraceptive
Description: Ethynil estradiol (EE)/norgestimate combination oral contraceptive is a 28-tablet cycle in which 1 oral tablet is taken daily; each containing 0.250 mg norgestimate and 0.035 mg EE for 21 days, after which a tablet only containing inert ingredients is taken for last 7 days of the 28 day cycle.
Study: NCT02573597

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Continuous or bolus administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Continuous or bolus administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Continuous or bolus administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Continuous or bolus administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: Continuous or bolus administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: Continuous or bolus administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: Continuous or bolus administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: Continuous or bolus administration
Study: NCT01068860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab 150 mg
Description: Single subcutaneous injection of Canakinumab 150 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab 150 mg
Description: Single subcutaneous injection of Canakinumab 150 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab 150 mg
Description: Single subcutaneous injection of Canakinumab 150 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab 150 mg
Description: Single subcutaneous injection of Canakinumab 150 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab 150 mg
Description: Single subcutaneous injection of Canakinumab 150 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Canakinumab
Description: Single subcutaneous injection of Placebo to Canakinumab.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Canakinumab
Description: Single subcutaneous injection of Placebo to Canakinumab.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Canakinumab
Description: Single subcutaneous injection of Placebo to Canakinumab.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Canakinumab
Description: Single subcutaneous injection of Placebo to Canakinumab.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Canakinumab
Description: Single subcutaneous injection of Placebo to Canakinumab.
Study: NCT04636788

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Venous sampling
Description: venous sampling of 12ml
Study: NCT03405831

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivabradine
Description: Ivabradine, oral tablets, 5 mg, coated in gelatine capsules to ensure blinding, 1 capsule twice a day, for a period of 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, gelatine capsules to ensure blinding, 1 capsule twice daily, for a period of 12 weeks
Study: NCT02105467

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Grazoprevir 100mg / Elbasvir 50 mg FDC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir 100mg / Elbasvir 50 mg FDC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Grazoprevir / Elbasvir 50 mg FDC
Study: NCT04445025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix 200 MG
Description: Elagolix 200mg twice daily orally for 60 days prior to beginning frozen embryo transfer preparation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide Acetate 3.75 MG/ML
Description: Leuprolide Acetate intramuscularly every 28 days (twice) prior to beginning frozen embryo transfer preparation

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Lab work
Description: Serum follicle stimulating hormone (FSH), estradiol, luteinizing hormone (LH), progesterone, human chorionic gonadotropin (hCG), serum for microarray analysis, complete blood count, and chemistry panel with liver functions levels will be drawn via blood draw

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lab work
Description: Serum follicle stimulating hormone (FSH), estradiol, luteinizing hormone (LH), progesterone, human chorionic gonadotropin (hCG), serum for microarray analysis, complete blood count, and chemistry panel with liver functions levels will be drawn via blood draw
Study: NCT04314037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cesol (Test)
Description: Participant will receive coated cesol tablet in sequence 1 (Day 1 and Day 15) and in sequence 2 (Day 8 and Day 22). A washout period of 7 days will be maintained between 4 treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cesol (Test)
Description: Participant will receive coated cesol tablet in sequence 1 (Day 1 and Day 15) and in sequence 2 (Day 8 and Day 22). A washout period of 7 days will be maintained between 4 treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biltricide (Reference)
Description: Participant will receive biltricide tablet in Sequence 1 (Day 8 and Day 22) and in sequence 2 (Day 1 and Day 15). A washout period of 7 days will be maintained between 4 treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biltricide (Reference)
Description: Participant will receive biltricide tablet in Sequence 1 (Day 8 and Day 22) and in sequence 2 (Day 1 and Day 15). A washout period of 7 days will be maintained between 4 treatment periods.
Study: NCT03566030

Intervention type: DRUG
Intervention: Tenofovir disoproxil fumarate 300mg
Description: Administered Tenofovir disoproxil fumarate 300 mg QD

Intervention type: DRUG
Intervention: Tenofovir Alafenamide 25 mg
Description: Administered Tenofovir Alafenamide 25 mg QD
Study: NCT02843048

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training program
Description: Participants allocated to the Exercise training plus standard medical care group will undergo an exercise-training program of 11 months duration, 3 sessions/week, and 60 minutes/session, starting one month after the surgery. Each exercise session will be supervised and will include 5 major components: i) warm-up, ii) multidirectional jumps, iii) balance, iv) strength and, v) cool down. This structure is planned to meet two main objectives: i) enhance bone formation and, ii) reduce fall risk by improving muscle strength, cardiorespiratory fitness and balance.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical care
Description: Standard follow-up medical care following bariatric surgery
Study: NCT02566772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS3681
Description: TAS3681 will be provided as 100 mg tablets to be administered orally in 28-day cycles. The number of cycles is approximately 6, or until discontinuation criteria is met.
Study: NCT00470470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01296087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-6987
Description: TC-6987 50 mg capsule given once daily on Days 1 to 28

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsule given once daily on Days 1 to 28